Results 251 to 260 of about 94,421 (295)

Substrate based inhibitors of smooth muscle myosin light chain kinase

Biochemical and Biophysical Research Communications, 1992
Activation of myosin light chain kinase is a prerequisite for smooth muscle activation. In this study, short peptide analogs of the phosphorylation site of the myosin light chain were studied for their effects on several contractile protein systems. The peptides inhibited phosphorylation of isolated ventricular and smooth muscle myosin light chains by ...
S, Moreland, M, Ikebe, J T, Hunt, R S, Moreland   +3 more
openaire   +2 more sources

Advances in Cardiovascular Pharmacotherapy. I. Cardiac Myosin Inhibitors

Journal of Cardiothoracic and Vascular Anesthesia
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy. The disease is characterized by asymmetric left ventricular (LV) remodeling with myocyte disarray and interstitial fibrosis, a hypercontractile state, dynamic subaortic obstruction of the LV outflow tract, impaired LV diastolic function, atrial and ventricular arrhythmias ...
Paul S, Pagel, Dustin, Hang, Julie K, Freed, George J, Crystal   +3 more
openaire   +2 more sources

Peptidase-resistant peptide inhibitors of myosin light chain kinase

Russian Journal of Bioorganic Chemistry, 2010
Myosin light chain kinase (MLCK) is the key regulator of various forms of cell motility including endothelial and epithelial permeability in particular. One of the potential MLCK inhibitors to be used in humans is a membrane permeable peptide H-RKKYKYRRK-NH2 (L-PIK).
A. V. Sekridova, M. V. Sidorova, A. A. Az’muko, A. S. Molokoedov, V. N. Bushuev, A. V. Marchenko, O. V. Shcherbakova, V. P. Shirinsky, Zh. D. Bespalova   +8 more
openaire   +1 more source

First-in-class cardiac myosin inhibitor reduces symptoms of HCM

Nature Reviews Cardiology, 2020
Mavacamten, a first-in-class cardiac myosin inhibitor, reduces symptoms and improves health status in patients with obstructive hypertrophic cardiomyopathy, according to findings from the EXPLORER-HCM trial.
openaire   +2 more sources

Myosin inhibitor flexes, myosin activator flops

Nature Reviews Drug Discovery, 2020
openaire   +1 more source

Erster kardialer Myosin-Inhibitor

CME, 2023
openaire   +1 more source

FDA approves first cardiac myosin inhibitor

Nature Reviews Drug Discovery, 2022
openaire   +1 more source

FDA okays first cardiac myosin inhibitor

Nature Biotechnology, 2022
openaire   +1 more source

Myosin Inhibitors: The Next Generation.

Journal of the American College of Cardiology, 2023
Ajith, Nair, Lola, Xie, Jorge E, Silva Enciso   +2 more
openaire   +1 more source

Cardiac Myosin Inhibitors for Managing Obstructive Hypertrophic Cardiomyopathy

JACC: Heart Failure, 2023
John W. Ostrominski, Ruby Guo, Perry M. Elliott, Carolyn Y. Ho   +3 more
openaire   +1 more source